secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2023-05-22T23:59:59+00:00
Accession:  0001437749-23-015468
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics dismisses BDO, appoints Ernst & Young as new auditor
------------------------------------------------------------------------

- On May 17, 2023, Atossa dismissed BDO USA LLP as independent auditor; no accounting disagreements.
- BDO's 2021/2022 audit reports were unqualified; no adverse opinions or scope modifications.
- A 2020 material weakness in internal controls over financial reporting was remediated by end of 2021.
- EY appointed as new auditor for fiscal year ending December 31, 2023.
- No prior consultations with EY on accounting principles or disagreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923015468/0001437749-23-015468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000143774923015468/atos20230515_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-015468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer